About this trial
* Hypertension is the single largest contributor to cardiovascular disease and death. While adequate control of hypertension reduces risk of disease, many patients have uncontrolled hypertension. This is often due to medication non-adherence. Left undetected, patients are prescribed additional medications, and referred to multiple specialists for investigations - leading to increased healthcare costs. Hence, detecting non-adherence to antihypertensive medications is important. However, patient history, patient recall, or questionnaires, are often inaccurate. Most recently, urine measurements of antihypertensive drug levels, using mass spectrometry, has been established as the gold standard to assess medication adherence. The one-time urine test for medication adherence is ideal: It's convenient, non-invasive, economical, and can be easily performed in a clinic setting. By improving blood pressure control, this will lead to reductions in healthcare visits, avoidance of catastrophic cardiovascular events. Ultimately, this translates to significant economic savings for both patients with hypertension and the healthcare system. * Therefore, the investigators hypothesize that the implementation of urine adherence testing coupled with targeted counselling will improve the adherence and blood pressure control in hypertension. To do this, the investigators aim to (1) evaluate for medication adherence in 312 participants with recent stroke and hypertension; (2) evaluate for medication non-adherence in participants with uncontrolled hypertension; and (3) assess if detection of non-adherence can improve hypertension control.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age of 21 - 80 years
Systolic blood pressure of ≥140 mmHg or average systolic blood pressure ≥135 mmHg, or diastolic blood pressure ≥90 mmHg or average diastolic blood pressure ≥85 mmHg, on at least two measurements
Currently taking 2 or more hypertension medications
Able to provide informed consent.
Disqualifiers
Significant kidney impairment with eGFR of less than 45mL/min/1.73m2 or on dialysis
Known history of chronic liver disease
Trial design
Single group
Treatments tested in this trial
mass spectrometry analysis
Other interventionThe collected urine samples will be analyzed to determine medication adherence during study visits
Treatment groups
Trial outcomes
Primary outcomes
Change in adherence rate
This is the difference in the adherence rates at enrollment and at the end of the study
The change in systolic blood pressure
This is the difference in systolic blood pressure between enrollment and the last follow up visit at 6 months
The change in diastolic blood pressure
This is the difference in diastolic blood pressure between enrollment and the last follow up visit at 6 months
Sponsors and contacts
Click on the lead sponsor to view all of their trials.